Nicox (NICXF) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NICXF Nicox SA NICXF
36 GF Score
Price $0.30
GF Value $0.61
! 2 Warning Signs
View Full Analysis

What is Nicox DeferredTaxAndRevenue?

Nicox NICXF 36 DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus rates NICXF with a GF Score™ of 36/100 and a GF Value™ of $0.61. The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Nicox's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Nicox DeferredTaxAndRevenue Related Terms

Nicox DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Nicox's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox DeferredTaxAndRevenue Chart

Nicox Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nicox Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NICXF
36GF Score
Nicox SA NICXF
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Nicox (NICXF) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Nicox.
Is Nicox's DeferredTaxAndRevenue too high?
Nicox's current DeferredTaxAndRevenue is $0.00 Mil. Overall, Nicox has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Nicox's DeferredTaxAndRevenue compare to VRTX and REGN?
Nicox's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Nicox. Nicox's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nicox stock overvalued right now?
Nicox (NICXF) has a current DeferredTaxAndRevenue of $0.00 Mil. The stock's GF Value™ is $0.61, compared to a current price of $0.30 — trading 50.8% below its estimated fair value. The current DeferredTaxAndRevenue is $0.00 Mil. Nicox's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Nicox (NICXF), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nicox (NICXF) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of $0.30 is trading 50.8% below its estimated GF Value™ of $0.61.

Key valuation signals for NICXF:

  • DeferredTaxAndRevenue: $0.00 Mil
  • GF Value™: $0.61 vs. price of $0.30 (50.8% below fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the NICXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
36GF Score

Get the complete analysis for NICXF

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.61
GF Value